Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311280 | 0.88 | DRD2 (0.40) | CACNA1GCACNA1HCACNA1IHTR2CCCR5 | |
| SCHEMBL6311540 | 0.86 | CCR5 (0.46) | CACNA1GCACNA1HCACNA1IHTR2CS1PR5 | |
| SCHEMBL6310196 | 0.82 | CACNA1G (0.44) | CACNA1GCACNA1HCACNA1IHTR2CS1PR5 | |
| SCHEMBL5747751 | 0.80 | CACNA1G (0.43) | CACNA1GCACNA1HCACNA1IHTR2CS1PR5 | |
| SCHEMBL6309596 | 0.78 | CACNA1G (0.43) | CACNA1GCACNA1HCACNA1IHTR2C | |
| SCHEMBL6310201 | 0.73 | CACNA1G (0.44) | CACNA1GCACNA1HCACNA1IHTR2CPSEN1 | |
| SCHEMBL6317296 | 0.71 | DRD2 (0.41) | CACNA1GCACNA1HCACNA1IS1PR5POLB | |
| SCHEMBL1896746 | 0.71 | USP30 (0.51) | S1PR5S1PR1 | |
| SCHEMBL1897605 | 0.71 | S1PR5 (0.49) | S1PR5S1PR1POLB | |
| SCHEMBL13041176 | 0.71 | S1PR5 (0.49) | S1PR5S1PR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | CACNA1G 1297/4885CACNA1H 1149/4885CACNA1I 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.